Role of human epidermal growth factor receptor 3 in treatment resistance of anaplastic lymphoma kinase translocated non-small cell lung cancer

BACKGROUND: ALK tyrosine kinase inhibitors (TKI) have revolutionized the treatment of ALK+ non-small cell lung cancer (NSCLC), and therapy resistance occurs in virtually all patients. Multiple TKI resistance mechanisms have been characterized, including ERBB receptor coactivation. In this study, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Honkanen, Tiia J, Luukkainen, Milla E K, Koivunen, Jussi P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512822/
https://www.ncbi.nlm.nih.gov/pubmed/37722715
http://dx.doi.org/10.1080/15384047.2023.2256906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512822/
https://www.ncbi.nlm.nih.gov/pubmed/37722715
http://dx.doi.org/10.1080/15384047.2023.2256906

Ejemplares similares